Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · BridgeBio Pharma, Inc. (BBIO)

BridgeBio's oral infigratinib NDA accepted for priority review; FDA target date Feb 4, 2027

Positive Impact 3 of 5 legal/regulatory Written later

BridgeBio announced the FDA accepted its New Drug Application for oral infigratinib for children with achondroplasia with Priority Review, setting a PDUFA target action date of February 4, 2027. The company says the drug met its Phase 3 PROPEL 3 primary endpoint, but the filing does not describe financial results or a financial effect, so the update is mainly a regulatory milestone for shareholders.

Key points

  • FDA accepted the NDA with Priority Review; PDUFA target action date is February 4, 2027
  • PROPEL 3 met its primary endpoint: LS mean treatment difference of +1.74 cm/year and mean treatment difference of +2.10 cm/year in annualized height velocity (p<0.0001)
  • Oral infigratinib has Breakthrough Therapy Designation; BridgeBio plans to submit a Marketing Authorization Application to the EMA in Q4 2026
  • Approval is not assured; the filing notes the FDA may not approve the drug on the anticipated timeline or at all

The filing

CompanyBridgeBio Pharma, Inc. (BBIO)
Form8-K, current report
Filed with the SECOct 13, 2026, 6:01 AM ET
Accession number0001140361-26-039334

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.